Zenas BioPharma is a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world. The company has a deep pipeline of innovative autoimmune therapeutics and is rapidly advancing seven pipeline programs, including three with worldwide rights. Zenas aims to transform the lives of patients living with autoimmune diseases.

Lonnie Moulder Jr

Zenas BioPharma

FiercePharma provides news and information related to the pharmaceutical industry, including topics like vaccines, drug delivery, and manufacturing, self-described as highlighting corporations driving change in healthcare.

FiercePharma

The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the NASDAQ Biotechnology IndexÂ®.
 The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund&#39;s investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

ProShares UltraPro Short Nasdaq Biotechnology

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies for patients around the world. Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com.

Metric
Company Name	Zenas BioPharma	FiercePharma
Symbol
MSH ID	COM:ZENASBIO	COM:FIERCEPHARMA
Market	STOCKS	PRIVATE
Sector	Healthcare	Commercial & Professional Services
Industry	Biopharmaceutical	Pharmaceuticals
Country	US	US
Stage	Series C
Employee Count	1
Website	zenasbio.com	fiercepharma.com
LinkedIn	zenas-biopharma
Founders

Metric
Market Cap	2.50M
Enterprise Value
Monthly Web Traffic	23.40K	484.53K
Web Traffic Growth	0.75	-0.10
Valuation
Raised Capital	200M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

ZBIO

COM:ZENASBIO

Zenas BioPharma

Last Close

10.44

22/11 21:00

Market Cap

2.50M

Beta: -

Volume Today

785.07K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue